Ardsley Advisory Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

Ardsley Advisory Partners’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-510,000	Closed	-$10.2M	–	177
2018 Q3	$10.2M	Buy	510,000 +250,000	+96%	+$5.87M	1.38%	22
2018 Q2	$6.72M	Buy	260,000 +40,000	+18%	+$1.11M	1.01%	36
2018 Q1	$5.25M	Buy	220,000 +65,000	+42%	+$2.05M	0.79%	44
2017 Q4	$5.25M	Buy	+155,000	New	+$4.33M	0.64%	40
2017 Q3	–	Sell	-15,000	Closed	-$262K	–	172
2017 Q2	$262K	Hold	15,000	–	–	0.04%	121
2017 Q1	$263K	Hold	15,000	–	–	0.04%	123
2016 Q4	$254K	Hold	15,000	–	–	0.04%	106
2016 Q3	$246K	Buy	+15,000	New	+$228K	0.04%	128

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Ardsley Advisory Partners's ADMS Position: Q4 2018 in Review

Ardsley Advisory Partners sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 510,000 shares — an estimated $10.2M sold.

Ardsley Advisory Partners first reported a position in ADMS in Q3 2016 and held it in 8 quarters. The position peaked at $10.2M in Q3 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

Ardsley Advisory Partners reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 510,000 Adamas Pharmaceuticals shares in Q4 2018, an estimated $10.2M.
Ardsley Advisory Partners first reported a position in Adamas Pharmaceuticals in Q3 2016 and held it in 8 quarters.
Ardsley Advisory Partners's Adamas Pharmaceuticals position peaked at $10.2M in Q3 2018.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.